1. Home
  2. ICMB vs BOLD Comparison

ICMB vs BOLD Comparison

Compare ICMB & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Investcorp Credit Management BDC Inc.

ICMB

Investcorp Credit Management BDC Inc.

HOLD

Current Price

$1.31

Market Cap

30.7M

Sector

Finance

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.45

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICMB
BOLD
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
30.7M
36.5M
IPO Year
2013
2024

Fundamental Metrics

Financial Performance
Metric
ICMB
BOLD
Price
$1.31
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
45.3K
127.7K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
21.74%
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.43
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.20
$0.96
52 Week High
$3.12
$1.68

Technical Indicators

Market Signals
Indicator
ICMB
BOLD
Relative Strength Index (RSI) 30.88 50.05
Support Level $1.28 $1.40
Resistance Level $2.99 $1.55
Average True Range (ATR) 0.11 0.08
MACD -0.01 -0.01
Stochastic Oscillator 18.00 34.15

Price Performance

Historical Comparison
ICMB
BOLD

About ICMB Investcorp Credit Management BDC Inc.

Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: